TERAPIA ANTIMICROBIANA EMPIRICA EN PACIENTES CON COINFECCION BACTERIANA ASOCIADA A COVID 19
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Rev. Méd. La Paz
Abstract
Las evidencias sobre coinfecciones bacterianas y fúngicas en pacientes con infección por coronavirus informan un porcentaje general elevado de las mismas, en cualquier momento durante la hospitalización. Al tratarse de pacientes que con frecuencia requieren hospitalización prolongada y asistencia respiratoria, los antibióticos innecesarios en el momento de la hospitalización pueden aumentar el riesgo individual de Neumonía adquirida en el Hospital posterior causada por bacterias resistentes y otros eventos adversos. Por lo tanto, el uso adecuado de antimicrobianos se asocia a mayor éxito en el manejo de estos pacientes, Se revisan en este articulo las evidencias disponibles acerca del tratamiento antimicrobiano adecuado en los pacientes con COVID 19, con coinfecciones bacterianas.
SUMMARY Reviews of bacterial and fungal co-infections in patients with coronavirus infection report an overall high percentage of co-infections in COVID-19 patients at any time during hospitalization. As patients who often need prolonged hospitalization and respiratory support, unnecessary antibiotics at the time of hospitalization may increase the individual risk of subsequent hospital-acquired pneumonia caused by resistant bacteria and other adverse events. Therefore, the appropriate use of antimicrobials is associated with greater success in the management of these patients. This paper reviews the available evidence about the appropriate antimicrobial treatment in patients with COVID 19, with bacterial co-infections.
SUMMARY Reviews of bacterial and fungal co-infections in patients with coronavirus infection report an overall high percentage of co-infections in COVID-19 patients at any time during hospitalization. As patients who often need prolonged hospitalization and respiratory support, unnecessary antibiotics at the time of hospitalization may increase the individual risk of subsequent hospital-acquired pneumonia caused by resistant bacteria and other adverse events. Therefore, the appropriate use of antimicrobials is associated with greater success in the management of these patients. This paper reviews the available evidence about the appropriate antimicrobial treatment in patients with COVID 19, with bacterial co-infections.
Description
Vol. 27, No. 2